MYCN and neuroblastoma: For the large cohorts of HR-NB patients in those studies, [11, 16, 20, 39–41] the 5-year EFS rates of 24%-to-47% and the 5-year OS rates of 26%-to-60% were inferior to the outcome of the MYCN-amplified stage 2/3 patients in our series and in the report using ASCT+RT [9].